The Supplement Industry Hit $74 Billion — And the Evidence Gap Is Getting Harder to Ignore
US supplement sales reached $74.15 billion in 2025, with projections targeting $100 billion by 2029. But a new wave of decentralized clinical trials is finally closing the gap between consumer demand and scientific proof.
$74 Billion in Sales. How Much Evidence?
The US dietary supplement market reached $74.15 billion in 2025 sales, with industry projections targeting $100 billion by 2029. E-commerce platforms — including TikTok Shop — are reshaping how consumers discover, evaluate, and purchase supplements at a pace that traditional retail channels can't match.
But there's a structural problem underneath the growth: most supplement brands still can't point to clinical evidence for their finished formulations. They cite ingredient-level research — a study on ashwagandha here, a curcumin meta-analysis there — without demonstrating that their specific product, at their specific dose, produces measurable results.
That's the evidence gap. And it's getting harder to ignore.
A New Clinical Trial Model
The most interesting development in 2026 isn't a new ingredient. It's a new infrastructure for evidence generation.
PLT Health Solutions has partnered with Alethios, a decentralized clinical trial platform, to enable brands to run faster, more affordable clinical studies on finished supplement products. The model:
- Decentralized design — participants enroll remotely, reducing overhead
- Formula-specific evidence — testing the actual product, not just isolated ingredients
- Faster timelines — weeks to months, not years
- Brand-funded but independently conducted — separating marketing from science
This matters because the supplement industry's credibility problem isn't about bad products. It's about the gap between what brands claim and what they can prove about their specific formulation.
Where the Market Is Moving
Three trends worth watching:
1. Gut-Skin Axis Products Florastor launched "Digest + Skin Renew," targeting the gut-skin connection with a probiotic designed for both digestive and dermatological benefits. The holistic approach reflects consumer demand for supplements that address interconnected body systems rather than isolated symptoms.
2. Cognitive and Nootropic Gummies NOON WORLD expanded into 878 Target stores with a dual-layer gummy technology for nootropic and adaptogenic blends. The format innovation — higher concentration, faster release — signals that the delivery mechanism is becoming as important as the active ingredients.
3. Oral Microbiome Oraticx is building an oral probiotic line focused on the mouth's microbial ecosystem. The oral microbiome is increasingly linked to cardiovascular health, cognitive function, and systemic inflammation — making it a new frontier for supplement innovation.
The NORM Perspective
This is exactly why NORM exists. When a $74 billion industry grows at 7-9% annually and most products lack formula-specific evidence, consumers need an independent signal for claim proportionality.
We score brands on whether their marketing claims match their visible evidence — not whether the ingredients "work" in isolation, but whether the company's public claims are proportional to what they can actually demonstrate.
As decentralized clinical trials make evidence generation cheaper and faster, the brands that invest in formula-specific proof will separate from those still relying on borrowed ingredient research. Our leaderboard will reflect that shift.